Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q1 2016 · 10-Q
Revenue$0.00$0.00— vs Q1 2015 Net Income-$1.19M-$1.19MN/M vs Q1 2015 EPS Diluted$0.00$0.00— vs Q1 2015 Operating Income-$1,194,465N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
ended Mar 31, 2016 · filed May 13, 2016 · 43 d after period end